[Event Report] Making the ‘Silent Pandemic’ of AMR Heard: What Countries Leading the Charge Against AMR are Doing to Ensure their Populations are Protected (April 28, 2022)
date : 11/28/2022
Tags: AMR
![[Event Report] Making the ‘Silent Pandemic’ of AMR Heard: What Countries Leading the Charge Against AMR are Doing to Ensure their Populations are Protected (April 28, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-event-20220428-1-top.jpg)
*The report of this symposium has been published. (November 28, 2022)
On April 28, 2022, AMR Alliance Japan (Secretariat: Health and Global Policy Institute) held a symposium gathering experts from Japan and other countries that are leading the way in the fight against AMR. Participants from Japan, Germany, the United Kingdom, and the United States discussed each country’s AMR response, and possibilities for future collaborations in this space.
This symposium shared international best practices for stronger policy responses against AMR as well as trends of policy discussions on this issue. Moving forward, AMR Alliance Japan and HGPI will continue to work to make the ‘silent pandemic’ of AMR heard.
[Overview]
- Date and time: April 28, 2022; 18:00-19:30, JST
- Format: Online using the Zoom conferencing system
- Host: AMR Alliance Japan / Health and Global Policy Institute (HGPI)
- Languages: English and Japanese (simultaneous interpretation will be provided)
- Participation fee: Free
[Program]
18:00-18:05 Welcome and Introduction
Matt McEnany (Senior Manager, Health and Global Policy Institute / AMR Alliance Japan)
18:05-18:10 Opening Remarks
Yasuhisa Shiozaki (Former Member, House of Representatives / Member, WHO Global Leaders Group on Antimicrobial Resistance)
18:10-18:20 – Looking Back on the UK’s G7 Presidency – Future Plans for AMR Policy
Sally Davies (UK Special Envoy on Antimicrobial Resistance / Member, WHO Global Leaders Group on Antimicrobial Resistance)
18:20-18:30 – AMR in Germany’s G7 Presidency
Dagmar Reitenbach (Head of Division Global Health, Federal Ministry of Health (BMG), Germany)
18:30-18:40 – AMR Policy Priorities in the United States and Across Europe
Kevin Outterson (Executive Director, CARB-X)
18:40-18:50 – Japanese Leadership on AMR Countermeasures
Norio Ohmagari (Director, Department of Infectious Diseases, National Center for Global Health and Medicine / Director, AMR Clinical Reference Center, National Center for Global Health and Medicine)
18:50 – 19:30 Panel Discussion / Q&A
Panelists
- Sally Davies (UK Special Envoy on Antimicrobial Resistance / Member, WHO Global Leaders Group on Antimicrobial Resistance)
- Dagmar Reitenbach (Head of Division Global Health, Federal Ministry of Health (BMG), Germany)
- Kevin Outterson (Executive Director, CARB-X)
- Norio Ohmagari (Director, Department of Infectious Diseases, National Center for Global Health and Medicine / Director, AMR Clinical Reference Center, National Center for Global Health and Medicine)
- Eiji Hinoshita (Assistant Minister for Global Health and Welfare, Ministry of Health, Labour and Welfare)
Moderator
Matt McEnany (Senior Manager, Health and Global Policy Institute / AMR Alliance Japan)
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Policy Recommendations] The 6 Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Obesity Control (November 1, 2023)
- [Announcement] HGPI Declares the Ministry of the Environment-led ‘Deco-Katsu Declaration’ and Participation in the ‘Deco-Katsu’ Supporters (October 16, 2023)
- [Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Recommendations] The Future of Dementia Policy 2022: Deepening Dementia Policies Centered on People Living with Dementia and their Families to Lead Global Society (July 13, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
Featured Posts
-
2023-10-31
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
-
2023-11-01
[Policy Recommendations] The 6 Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Obesity Control (November 1, 2023)
-
2023-11-02
[Event Report] Health Information Project 1st Global Sage Meetings for “Co-creating Health Information Right” (July 21, 2023)
-
2023-11-06
[Event Report] The Project for Considering the Future of Precision Medicine with Industry, Government, Academia, and Civil Society – The Policy Dialogue Event “Challenges and Prospects for the Improving Patient Access to Genomic Cancer Medicine” (October 11, 2023)
-
2023-11-10
[Event Report] Planetary Health Expert Meeting “Healthy Planet, Healthy People: Building a New Collaborative Framework Focused on Climate Change and Health in the Asia-Pacific Region” (November 2, 2023)